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Abstract  1 
Background: Several chronic disease states have been identified as 2 
pneumococcal vaccination indications due to their ability to increase 3 
pneumococcal disease development and subsequent mortality. However, the risk 4 
of mortality according to the number of these disease states present is unknown. 5 
We sought to determine the impact of concomitant, multiple risk factors (stacked 6 
risks) for pneumococcal disease on 30-day mortality in adults. 7 
 8 
Methods: This was a national case-control study of unvaccinated older Veterans 9 
(≥50 years of age) admitted to Veterans Affairs medical centers from 2002 to 2011 10 
with serious pneumococcal infections (pneumonia, bacteremia, meningitis) based 11 
on positive S. pneumoniae blood, cerebrospinal fluid, or respiratory cultures, 12 
respectively. Cases were those not alive 30 days following culture, while controls 13 
were alive. Using logistic regression, we quantified risk of 30-day mortality among 14 
patients with stacked risk factors, including age ≥ 65 years, alcohol abuse, chronic 15 
heart disease, chronic liver disease, chronic respiratory disease, diabetes mellitus, 16 
immunodeficiency, and smoking. 17 
 18 
Results: We identified 9,730 serious pneumococcal infections, with an overall 30-19 
day mortality rate of 18.6% (1,764 cases, 7,966 controls). Infection types included 20 
pneumonia (62%), bacteremia (26%), and bacteremic pneumonia (11%). Along 21 
with eight individual risk factors, we assessed 247 combinations of risk factors. 22 
Most cases (85%) and controls (74%) had at least two risk factors. Mortality 23 
increased as risks were stacked, up to six risk factors (one: OR 1.5, CI 1.08-2.07; 24 
two: OR 2.01, CI 1.47-2.75; three: OR 2.71, CI 1.99-3.69; four: OR 3.27, CI 2.39-25 
4.47; five: OR 3.63, CI 2.60-5.07; six: OR 4.23, CI 2.69-6.65), with each additional 26 
risk factor increasing mortality an average of 55% (±13%).    27 
 28 
Conclusions: Among adults ≥ 50 years with serious pneumococcal disease, 29 
mortality risk increased approximately 55% as vaccination indications present 30 
increased. Mortality with six stacked indications was double that of two indications.   31 
 32 
Keywords: Risk Stacking, Pneumococcal Vaccination, Streptococcus 33 
pneumoniae, Mortality 34 
  35 
Introduction 36 
 Serious Streptococcus pneumoniae infections, including pneumonia, 37 
bacteremia, and meningitis, are a major cause of morbidity and mortality among 38 
older adults.[1-3] Since the 1980s, vaccines to prevent pneumococcal disease 39 
have been used on a global scale to mitigate the risks associated with these 40 
bacterial infections.[4] The Advisory Committee on Immunization Practices (ACIP) 41 
recommends administration of the pneumococcal vaccination to adults with certain 42 
risk factors for pneumococcal disease, including age ≥ 65 years, alcoholism, heart 43 
disease and heart failure, chronic respiratory disease, hepatic dysfunction, 44 
immunodeficiency, and smoking, in an effort to prevent invasive pneumococcal 45 
disease (IPD) and subsequent poor outcomes.[3]  46 
 Recent research has revealed that the presence of multiple, concomitant 47 
risk factors (risk stacking), particularly those conditions identified by ACIP as 48 
indications for pneumococcal vaccination, increases the likelihood of developing 49 
pneumococcal disease beyond the risk posed by individual risk factors alone.[5, 6] 50 
As our population ages, it is becoming more common for patients to have two or 51 
more risk factors.[6] However, the impact of risk stacking on outcomes, namely 52 
mortality, of adults who end up developing pneumococcal disease remains 53 
unknown. Furthermore, current data on risk stacking are limited in that there is no 54 
information regarding the impact of risk stacking “at-risk” conditions (e.g., 55 
alcoholism, heart disease, liver disease, cigarette smoking) with “high-risk” 56 
conditions (e.g., immunodeficiency).[5-7] As such, the purpose of this study was 57 
to quantify the impact of stacking risk factors for developing pneumococcal disease 58 
on 30-day mortality among unvaccinated older adults. 59 
 60 
Methods 61 
Using national Veterans Health Administration databases, we conducted a 62 
nested case-control study of older Veterans (age ≥ 50 years) with positive S. 63 
pneumoniae blood, cerebrospinal fluid, or respiratory cultures between January 1, 64 
2002 and December 31, 2011. We defined serious pneumococcal infections as 65 
culture-positive pneumonia, bacteremia, and meningitis.  Cases were those 66 
individuals who died from any cause within 30 days of positive culture, and controls 67 
were those alive at 30 days. Patients were allowed to be included in the study 68 
multiple times if they had multiple positive cultures. Positive cultures from the same 69 
patient within a 30-day period were considered the same infection. We utilized 70 
national VA datasets, created from electronic medical records and administrative 71 
data, to collect patient demographics, health factors, medical history, vaccination 72 
history, medication use, clinical outcomes, and culture data. Pneumonia was 73 
identified from positive sputum cultures in addition to International Disease 74 
Classification, Ninth Revision (ICD-9) diagnosis codes. Bacteremia and meningitis 75 
were defined by positive blood and cerebrospinal fluid cultures, respectively. 76 
Patients receiving a pneumococcal vaccination within five years of positive culture 77 
were excluded. We utilized ICD-9 and procedure codes to identify the presence of 78 
disease states within one year of the positive culture date. Medication use within 79 
30 days of positive culture, particularly the use of immunosuppressants 80 
(corticosteroids, monoclonal antibodies, antineoplastic agents), was also 81 
assessed. 82 
We quantified the impact of individual, as well as combinations of multiple 83 
risk factors (stacked risks) for developing pneumococcal disease on 30-day all-84 
cause mortality. Selected risk factors were those that were previously identified as 85 
commonly occurring among older Veterans with pneumococcal disease, and that 86 
were also indications for pneumococcal vaccination identified by ACIP.[1, 3] These 87 
included age ≥ 65 years (age), alcohol abuse, chronic heart disease including 88 
chronic heart failure (CHD), chronic liver disease (CLD), chronic respiratory 89 
disease, including asthma and chronic obstructive pulmonary disease (CRD), 90 
diabetes mellitus (DM), immunodeficiency (IC), and smoking.[3] Age was included 91 
as a dichotomous variable, as opposed to a continuous variable, to reflect the 92 
actual vaccination indication of age ≥ 65 years. Immunodeficiency was defined as 93 
the presence of a solid malignancy, hematologic malignancy, HIV, or an AIDS-94 
defining illness within one year of positive culture. Smoking status was defined as 95 
documentation of active cigarette smoking, smoking cessation counseling, or 96 
receipt of smoking cessation prescription products (varenicline, nicotine 97 
replacement products) within one year of positive culture. We determined all 98 
possible two, three, four, five, six, seven, and eight indication combinations and 99 
defined each combination as a unique variable. Odds ratios (ORs) and 95% 100 
confidence interval (CIs) were calculated using logistic regression. Separate 101 
models were run for each mutually exclusive combination of vaccine indications. 102 
The reference group for each model consisted of those individuals without any of 103 
the aforementioned risk factors. This common reference group was selected in 104 
order to quantify the impact of stacking different combinations of indications as 105 
compared to those with none of the aforementioned indications for vaccination. 106 
Risk factors were deemed significant at a two-tailed p-value of 0.05 or less. All 107 
statistical analyses were performed with SAS version 9.2 (SAS Institute Inc., Cary, 108 
NC, USA). 109 
Approval by the Institutional Review Board and Research and Development 110 
Committee of the Providence Veterans Affairs Medical Center was obtained prior 111 
to initiating the study. 112 
 113 
Results 114 
 We identified 9,730 serious pneumococcal infections in 9,468 unvaccinated 115 
individuals, with a 30-day mortality rate of 18.6% (1,764 cases and 7,966 controls; 116 
Table 1). The primary infection types, determined from positive cultures, included 117 
pneumonia (cases n=871, 49.4%; controls n=5,204, 65.3%), bacteremia (cases 118 
n=585, 33.2%; controls n=1,969, 24.7%), and bacteremic pneumonia (cases 119 
n=305, 17.3%; controls n=755, 9.5%). Meningitis accounted for <1% of infections 120 
among cases and among controls.  121 
 There were 574 episodes (5.9%; 49 cases, 2.8%, 525 controls, 6.6%) of 122 
pneumococcal disease among individuals with none of the eight aforementioned 123 
risk factors. In addition to the eight individual risk factors, there were 247 unique 124 
combinations of risk factors. There were three individual risk factors (age, CHD, 125 
and IC) and 89 stacked risks significantly associated with an increased risk of 126 
mortality (Figure 1 and Figure 2). One risk factor (smoking) was associated with a 127 
decreased risk of mortality (OR 0.52, CI 0.31 – 0.87).  128 
 The risk of 30-day mortality among patients with one of any of the eight risk 129 
factors was 50% higher compared to those with none of the eight risk factors (OR 130 
1.50 95% CI 1.08-2.07). The risk of 30-day mortality increased as risk factors were 131 
stacked, up to six risk factors (one: OR 1.50, CI 1.08-2.07; two: OR 2.01, CI 1.47-132 
2.75; three: OR 2.71, CI 1.99-3.69; four: OR 3.27, CI 2.39-4.47; five: OR 3.63, CI 133 
2.60-5.07; six: OR 4.23, CI 2.69-6.65). The addition of each risk factor increased 134 
the risk of 30-day mortality by an average of 55% (±13%; median: 56%, 135 
interquartile range 51%-60%), with the greatest increase between two and three 136 
stacked risk factors (70%). There were no statistically significant odds ratios 137 
among patients with seven (OR 1.65, CI 0.36-7.52) or eight (OR 2.14, CI 0.25-138 
18.71) risk factors.  139 
 Among the 89 significant stacked risks, age was the most common risk 140 
factor present (50/89; 56.2%), followed by IC (49/89, 55.1%), CRD (48/89, 53.9%), 141 
CHD (45/89, 50.6%), CLD and smoking (both 37/89, 41.6%), DM (32/89, 36%), 142 
and alcohol abuse (29/89, 32.6%). All risk factors were present at least once in 143 
significant two, three, four, five, and six stacked risks with the exception of 144 
smoking, which was not present in any two risk-factor combinations. Figure 3 145 
shows the distribution of each risk factor according to the number of risk factors 146 
present.  147 
Of all significant individual risk factors, immunodeficiency was the strongest 148 
predictor of 30-day mortality (OR 2.30, CI 1.47-3.58). Among stacked risks, 149 
alcoholism + CLD (OR 6.20, 3.25-11.92), Age + CLD + IC (OR 42.90, CI 4.69-150 
390.98), alcoholism + CLD + DM + IC (OR 32.10, CI 3.28-314.3), age + CLD + 151 
CRD + IC + smoking (OR 16.07, CI 2.62-98.5), and Age + Alcoholism + CLD + 152 
CRD + IC + smoking (OR 21.40, CI 1.91-240.56) were the strongest predictors of 153 
mortality for those with two, three, four, five, or six risk factors, respectively (Figure 154 
2). Results for all stacked risks are available in Appendix A. 155 
 156 
Discussion 157 
 We quantified the impact of stacking pneumococcal disease risk factors on 158 
30-day mortality in unvaccinated older Veterans with serious pneumococcal 159 
infections. Of the 8 individual risk factors assessed, 37.5% of them significantly 160 
increased the risk of death and of the 247 stacked risks, 35% significantly 161 
increased the risk of death. Current literature regarding predictors of mortality in 162 
the setting of pneumococcal disease is primarily related to the impact of individual 163 
predictors, particularly in the immunocompromised population, as well as those 164 
with invasive pneumococcal disease.[8-16] However, there is a dearth of 165 
information regarding outcomes of patients with multiple risk factors for 166 
pneumococcal disease and the subsequent impact of this risk stacking. To our 167 
knowledge, this study is the first to analyze the effect of risk factor combinations 168 
on mortality. As the current body of literature strongly supports the association 169 
between vaccination preventing invasive infections and subsequent mortality in the 170 
setting of individual risk factors, the importance of disease prevention in patients 171 
with multiple risk factors cannot be overstated.[1-3, 8, 10, 16] 172 
 Mortality increased in each phase of risk stacking, up to six risk factors. 173 
Compared to patients with none of the eight risk factors for the development of 174 
pneumococcal disease, those with two risk factors were twice as likely to die at 30 175 
days. Those with six risk factors were more than four times as likely to die 176 
compared to those with no risk factors, and almost three times more likely to die 177 
as those with a single risk factor. No seven or eight risk factor combinations were 178 
statistically significant. However, this is likely due to smaller sample sizes in the 179 
seven (n=16) and eight (n=6) stacked risk groups. As pointed out in a recent risk 180 
stacking study, combining the effects of two independent risk factors as odds ratios 181 
leads to a multiplicative effect, as odds ratios are calculated on a log scale.[5, 17] 182 
Risk factors that are not entirely independent, however, may not be multiplicative. 183 
Several risk factors we analyzed may often be seen together, including alcohol 184 
abuse and liver disease, as well as smoking and respiratory and/or heart disease. 185 
Our results demonstrated that as the odds ratio increased as risk factors were 186 
stacked. However, the increased risk was not multiplicative, as would be expected 187 
in the presence of related conditions.  188 
 Interestingly, smoking was associated with a lower risk of mortality in our 189 
study. However, it should be noted that these were also individuals without any of 190 
the other risk factors for pneumococcal disease, including heart disease or 191 
respiratory disease, which are well-established consequences of smoking and also 192 
contribute to mortality. Furthermore, we were unable to quantify the degree to 193 
which individuals smoked. To be considered a smoker, documentation of smoking 194 
cessation counseling, use of smoking cessation medication, or an ICD-9 diagnosis 195 
code within one year were necessary. As such, these patients may not have been 196 
smokers at the time of infection. Collectively, these caveats require that the 197 
association between smoking and risk of mortality within our study be interpreted 198 
with caution. 199 
 The results of our study demonstrate the impact of increasing numbers of 200 
pneumococcal disease risk factors on mortality among patients with serious 201 
pneumococcal infections. Once individuals develop a pneumococcal infection, 202 
there is a lasting negative impact. A recent study within the Veteran population 203 
found that patients with pneumococcal pneumonia who survived at least 30 days 204 
beyond infection had increased mortality compared to the expected survival for the 205 
average Veteran with similar demographics for up to ten years after recovering 206 
from the infection.[18] Furthermore, decreases in survival at ten years ranged from 207 
15% to 50% according to increases in pneumonia severity index (PSI), which 208 
accounts for risk factors also assessed in our study, including age, cardiac 209 
disease, and hepatic dysfunction.[18, 19] As such, disease prevention may have 210 
an extended positive impact on mortality.  211 
Pneumococcal vaccination may be particularly important in patients with 212 
multiple risk factors for pneumococcal disease. While the ACIP already 213 
recommends that individuals with the risk factors assessed in our study be 214 
vaccinated to prevent the development of pneumococcal disease, many adults 215 
remain unvaccinated.[1, 3] This may be due, in part, to a lack of a focused strategy 216 
for identifying those most at risk for poor outcomes. A study of 1,177 patients who 217 
developed invasive pneumococcal disease and also had an indication for the 218 
polysaccharide pneumococcal vaccination demonstrated that 52% were 219 
unvaccinated, and that 92% of these unvaccinated individuals had at least one 220 
opportunity to receive the vaccination in the 2 years prior to infection. Multivariate 221 
analysis revealed that alcohol abuse, metastatic malignancy, and those ≥ 65 years 222 
of age with no other indication were predictive of being unvaccinated, while 223 
chemotherapy and non-HIV immune dysfunction were predictive of previous 224 
vaccination.[20]  225 
According to current ACIP pneumococcal vaccination recommendations, 226 
patients in our study with cardiac, respiratory, and hepatic disease, along with 227 
those who smoke, and have diabetes mellitus or alcoholism would have been 228 
eligible to receive the 23-valent, pneumococcal polysaccharide vaccine (PPSV-229 
23). In addition, those 65 years of age and older, and those with 230 
immunocompromising conditions are recommended to receive both the PPSV-23 231 
and the 13-valent, pneumococcal conjugate vaccine (PCV-13). [3, 21] Further, all 232 
children 6 weeks and older are currently recommended to receive PCV-13 (PCV-233 
7 during our study period), thereby impacting development of pneumococcal 234 
disease at the population level through herd immunity.[22, 23] In the general 235 
population, pneumococcal vaccination, particularly with the conjugate vaccines, 236 
has been associated with substantial reductions in disease incidence through 237 
indirect protection.[23] However, the impact of herd immunity in the older Veteran 238 
population remains unclear, and further studies are needed to determine if these 239 
findings are consistent in this high-risk population. 240 
Considering that each additional risk factor in our study increased the risk 241 
of mortality by 55% in the presence of pneumococcal disease, thorough evaluation 242 
of a patient’s medical history must be performed to ensure that, barring any 243 
contraindications, all individuals with these risk factors are vaccinated. 244 
Furthermore, it is important to note that the greatest increase between stacked 245 
combinations occurred as patients went from two to three risk factors. Interestingly, 246 
our findings are consistent with two other risk stacking studies assessing the risk 247 
of developing pneumococcal disease, which showed that the greatest increase in 248 
the risk of disease development occurred when increasing from two to three 249 
disease states present.[6, 21] Increases in disease development ranged from 67% 250 
to 265% moving from two to three disease states across all age ranges.[6, 24] As 251 
such, our study provides further evidence that risk stacking poses a substantial 252 
threat in older adults, in whom multiple, chronic disease states are common.[1, 6, 253 
25] Furthermore, the results of our study may assist future efforts to increase 254 
pneumococcal vaccination by providing healthcare practitioners with an estimate 255 
of the quantified risk of mortality for patients with different combinations of risk 256 
factors for developing pneumococcal disease.   257 
Limitations of our study included the assessment of risk factors identified by 258 
ACIP as necessitating pneumococcal vaccination. However, there may be other 259 
conditions, or combinations of conditions, that collectively increase the risk of 260 
mortality in the setting of pneumococcal disease which were not assessed in our 261 
study. We utilized ICD-9 diagnosis to identify disease states, allowing for the 262 
possibility of misclassification bias due to potential inaccuracies. Also, our study 263 
likely underestimated the true number of patients with pneumococcal pneumonia, 264 
as we only included patients with a positive sputum culture and ICD-9 diagnosis 265 
code. Further, pneumococcal pneumonia may have been the source for some 266 
pneumococcal bacteremias, but without positive respiratory cultures, was not 267 
categorized as such Next, patients with multiple episodes of pneumococcal 268 
infection that were included in the study multiple times may have had a different 269 
risk profile than those with a single episode of infection. However, this impact is 270 
likely negligible, as the vast majority of patients only had one episode of infection 271 
(9,730 infections in 9,468 patients). Determining the risk of mortality in patients 272 
with more than six stacked risk factors was limited by small sample sizes within 273 
these groups. However, we believe the risk of mortality to likely be much higher 274 
than healthy individuals, as mortality increased in stacked risk factor groups with 275 
larger numbers. Next, as odds ratios only approximate relative risk, actual mortality 276 
risk may differ. It should also be noted that our analysis did not specifically adjust 277 
for pneumonia disease severity, such as with the Pneumonia Severity Index score. 278 
However, given that many of the risk factors included in our study are also part of 279 
this severity index, it is likely that pneumococcal disease severity also increased 280 
with the number of stacked risks. [26] Lastly, as we studied an older Veteran 281 
population, generalizability to the U.S. population as a whole is limited. 282 
 283 
 284 
Conclusion 285 
 In unvaccinated older Veterans with serious pneumococcal disease, the 286 
presence of multiple ACIP risk factors for developing pneumococcal disease was 287 
associated with higher 30-day all-cause mortality. The more indications for 288 
vaccination present, the greater the risk of death, which was almost three times 289 
higher among those with six stacked risk factors as opposed to a single risk factor. 290 
As multiple risk factors for pneumococcal disease are common among older 291 
adults, effective vaccination strategies for the prevention of infection are needed.   292 
 293 
Acknowledgement: The views expressed are those of the authors and do not 294 
necessarily reflect the position or policy of the United States Department of 295 
Veterans Affairs. This material is based upon work supported, in part, by the Office 296 
of Research and Development, Department of Veterans Affairs. JBM was 297 
supported by Office of Academic Affiliations, Department of Veterans Affairs, and 298 
HJM is supported in part by a VA New England Career Development Award. 299 
 300 
Funding: This study was supported, in part, by an Advancing Science through 301 
Pfizer Initiated Research (ASPIRE) grant from Pfizer Inc. 302 
 303 
Conflict of Interest:  Jacob Morton has no reported financial relationships 304 
relevant to this article. Haley Morrill has received research funding from Merck. 305 
Kerry LaPlante has received research funding and/or served as a scientific 306 
advisor or consultant for Merck (Cubist), BARD/Davol, Allergan (Forest 307 
Laboratories and Durata Therapeutics), The Medicines Company, and Pfizer Inc. 308 
Aisling Caffrey has received research funding from Pfizer Inc, Merck (Cubist), 309 
and The Medicines Company.  310 
 311 
 312 
  313 
References 314 
1. Morrill HJ, Caffrey AR, Noh E, LaPlante KL. Epidemiology of 315 
pneumococcal disease in a national cohort of older adults. Infect Dis Ther. 316 
2014; 3(1):19-33. 317 
2. Janoff EN, Musher DM. Streptococcus pneumoniae. In: Bennett JE, Dolin 318 
R, Blaser MJ. Mandell, Douglas, and Bennett's Principles and Practice of 319 
Infectious Diseases. 8 ed: Elsevier, 2015:2310-27. 320 
3. Centers for Disease Control and Prevention. Use of 13-Valent 321 
Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal 322 
Polysaccharide Vaccine Among Adults Aged ≥65 Years: 323 
Recommendations of the Advisory Committee on Immunization Practices 324 
(ACIP). MMWR Morb Mort Wkly Rep. 2014; (63):822-5. 325 
4. World Health Organization. Pneumococcal vaccines WHO position paper. 326 
Weekly Epidemiological Record. 2012; 87(14):129-44. 327 
5. Curcio D, Cane A, Isturiz R. Redefining risk categories for pneumococcal 328 
disease in adults: critical analysis of the evidence. Int J Infect Dis. 2015; 329 
37:30-5. 330 
6. Pelton SI, Shea KM, Weycker D, Farkouh RA, Strutton DR, Edelsberg J. 331 
Rethinking risk for pneumococcal disease in adults: the role of risk 332 
stacking. Open Forum Infect Dis. 2015; 2(1):ofv020. 333 
7. Shea KM, Edelsberg J, Weycker D, Farkouh RA, Strutton DR, Pelton SI. 334 
Rates of pneumococcal disease in adults with chronic medical conditions. 335 
Open Forum Infect Dis. 2014; 1(1):ofu024. 336 
8. van de Beek D, de Gans J, Spanjaard L, Weisfelt M, Reitsma JB, 337 
Vermeulen M. Clinical features and prognostic factors in adults with 338 
bacterial meningitis. N Engl J Med. 2004; 351(18):1849-59. 339 
9. Kalin M, Ortqvist A, Almela M, et al. Prospective study of prognostic 340 
factors in community-acquired bacteremic pneumococcal disease in 5 341 
countries. J Infect Dis. 2000; 182(3):840-7. 342 
10. Hanada S, Iwata S, Kishi K, et al. Host Factors and Biomarkers 343 
Associated with Poor Outcomes in Adults with Invasive Pneumococcal 344 
Disease. PLoS One. 2016; 11(1):e0147877. 345 
11. Chi RC, Jackson LA, Neuzil KM. Characteristics and outcomes of older 346 
adults with community-acquired pneumococcal bacteremia. J Am Geriatr 347 
Soc. 2006; 54(1):115-20. 348 
12. Rudnick W, Liu Z, Shigayeva A, et al. Pneumococcal vaccination 349 
programs and the burden of invasive pneumococcal disease in Ontario, 350 
Canada, 1995-2011. Vaccine. 2013; 31(49):5863-71. 351 
13. Lin SH, Liao WH, Lai CC, et al. Comparison of clinical features, 352 
antimicrobial susceptibility, serotype distribution and outcomes of patients 353 
with hospital- and community-associated invasive pneumococcal disease. 354 
Int J Antimicrob Agents. 2010; 36(2):119-23. 355 
14. Turett GS, Blum S, Fazal BA, Justman JE, Telzak EE. Penicillin resistance 356 
and other predictors of mortality in pneumococcal bacteremia in a 357 
population with high human immunodeficiency virus seroprevalence. Clin 358 
Infect Dis. 1999; 29(2):321-7. 359 
15. Kumashi P, Girgawy E, Tarrand JJ, Rolston KV, Raad, II, Safdar A. 360 
Streptococcus pneumoniae bacteremia in patients with cancer: disease 361 
characteristics and outcomes in the era of escalating drug resistance 362 
(1998-2002). Medicine. 2005; 84(5):303-12. 363 
16. Shigayeva A, Rudnick W, Green K, et al. Invasive Pneumococcal Disease 364 
Among Immunocompromised Persons: Implications for Vaccination 365 
Programs. Clin Infect Dis. 2016; 62(2):139-47.  366 
17. Campbell MJ. Teaching logistic regression. International Association for 367 
Statistical Education Conference Proceedings, ICOT 5. 1998. 368 
18. Sandvall B, Rueda AM, Musher DM. Long-term survival following 369 
pneumococcal pneumonia. Clin Infect Dis. 2013; 56(8):1145-6. 370 
19. Aujesky D, Fine MJ. The pneumonia severity index: a decade after the 371 
initial derivation and validation. Clin Infect Dis. 2008; 47 Suppl 3:S133-9. 372 
20. Kyaw MH, Greene CM, Schaffner W, et al. Adults with invasive 373 
pneumococcal disease: missed opportunities for vaccination. Am J Prev 374 
Med. 2006; 31(4):286-92. 375 
21. Centers for Disease Control and Prevention. Use of 13-valent 376 
pneumococcal conjugate vaccine and 23-valent pneumococcal 377 
polysaccharide vaccine for adults with immunocompromising conditions: 378 
recommendations of the Advisory Committee on Immunization Practices. 379 
MMWR Morb Mort Wkly Rep. 2012; 61(40): 816-819. 380 
22. Centers for Disease Control and Prevention. Prevention of pneumococcal 381 
disease among infants and children – use of 13-valent pneumococcal 382 
conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine: 383 
recommendations of the Advisory Committee on Immunization Practices. 384 
MMWR Morb Mort Wkly Rep. 2010; 59(RR11): 1-18. 385 
23. Fine P, Eames K, Heymann DL. “Herd immunity”: a rough guide. Clin 386 
Infect Dis. 2011; 52: 911-6. 387 
24. Pelton SI, Shea KM, Farkouh RA, et al. Rates of pneumonia among 388 
children and adults with chronic medical conditions in Germany. BMC 389 
Infect Dis. 2015; 15:470. 390 
25. Centers for Disease Control and Prevention. CDC National Health Report: 391 
Leading Causes of Morbidity and Mortality and Associated Behavioral Risk 392 
and Protectie Factors-United States, 2005-2013. Morbidity and Mortality 393 
Weekly Report. 2014; 63(4). 394 
26. Fine MJ, Auble TF, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. 395 
A prediction rule to identify low-risk patients with community-acquired 396 
pneumonia. N Engl J Med. 1997; 336(4):243-50. 397 
Table 1. Demographics of unvaccinated older adults with pneumococcal 
disease. 
 
 Alive at 30 
days 
(n=7,966) 
Not alive at 30 
days 
(n=1,764) 
Age (years), (SD) 67 (± 11) 71 (± 11)* 
Gender, Male  7,795 (97.5) 1,740 (98.6)* 
Race   
    American Indian 98 (1.2) 14 (0.8) 
    Asian or Pacific Islander 63 (0.8) 11 (0.6) 
    Black 1,054 (13.2) 238 (13.5) 
    White 6,297 (79.0) 1,354 (76.8)* 
    Unknown 454 (5.7) 147 (8.3)* 
Pneumococcal Disease Risk 
Factors within previous year 
  
    Alcohol abuse 1,261 (15.8) 313 (17.7)* 
    Chronic heart disease 1,999 (25.1) 611 (34.6)* 
    Chronic heart failure 1,324 (16.6) 489 (27.7)* 
    Chronic liver disease, any  
    severity 
705 (8.9) 320 (18.1)* 
    Chronic respiratory disease 3,609 (45.3) 911 (51.6)* 
    Diabetes mellitus 1,709 (21.5) 476 (27.0)* 
    Immunodeficiency 2,535 (31.8) 747 (42.3)* 
    Cigarette smoking 3,777 (47.4) 674 (38.2)* 
Note: Results reported as n (%) unless otherwise specified 
 
*p < 0.05. 
Figure 1. Risk of 30-day mortality in unvaccinated adults with one 
pneumococcal disease risk factor. 
 
 
 
CI, Confidence Interval; OR, Odds Ratio 
 
Lower Mortality 
Risk 
Greater Mortality 
Risk 
Figure 2. Risk of 30-day mortality in unvaccinated adults with multiple pneumococcal disease risk factors. 
 Less Mortality 
Risk 
Greater Mortality 
Risk 
Age, Age ≥ 65 years; CHD, Chronic heart disease; CI, Confidence Interval; CLD, Chronic liver disease; CRD, Chronic 
respiratory disease; DM, Diabetes mellitus; IC, Immunodeficiency; OR, Odds Ratio 
*Includes 3 selected statistically significant OR (CI does not contain 1) from each numerical category of risk factors present. 
No statistically significant seven or eight risk factor combinations. See supplemental appendix for risk for all unique 
combinations. 
 
Figure 3. Frequency of stacked pneumococcal disease risk factors in 
unvaccinated adults. 
 
Age, Age ≥ 65 years; CHD, Chronic Heart Disease; CLD, Chronic Liver Disease; 
CRD, Chronic Respiratory Disease; DM, Diabetes Mellitus; IC, Immunodeficiency 
Includes only stacked risk combinations which significantly increased the risk of 
30-day mortality (p < 0.05). No statistically significant seven or eight risk factor 
combinations. 
 
 
 
 
 
 
 
 
 
Appendix A. Risk of 30-day mortality for all combinations of risk factors for 
developing pneumococcal disease. 
  
Alive at 
30 days 
(n=7,966) 
Not alive 
at 30 
days 
(n=1,764) ORa 95% CI 
No Risk factors 525 (6.6) 49 (2.8) Reference Reference 
Two Risk factors 
1,969 
(24.7) 
370 
(21.0) 2.01 1.47-2.75* 
Age + Alcoholism  22 (0.3) 9 (0.5) 4.38 1.91-10.04* 
Age + CHD  111 (1.4) 51 (2.9) 4.92 3.16-7.66* 
Age + CLD  < 5 < 5 16.07 2.62-98.49* 
Age + CRD  262 (3.3) 57 (3.2) 2.33 1.55-3.51* 
Age + DM  75 (0.9) 29 (1.6) 4.14 2.47-6.96* 
Age + IC 323 (4.1) 56 (3.2) 1.86 1.24-2.79* 
Age + Smoking  217 (2.7) 16 (0.9) 0.79 0.44-1.42 
Alcoholism + CHD  6 (0.08) < 5 1.79 0.21-15.13 
Alcoholism + CLD  31 (0.4) 18 (1.0) 6.22 3.25-11.92* 
Alcoholism + CRD  24 (0.3) < 5 1.34 0.39-4.61 
Alcoholism + DM  < 5 0 n/a n/a 
Alcoholism + IC 14 (0.2) 0 n/a n/a 
Alcoholism + Smoking  141 (1.8) 14 (0.8) 1.06 0.57-1.98 
CHD + CLD  < 5 < 5 10.71 1.48-77.69* 
CHD + CRD  32 (0.4) 6 (0.3) 2.01 0.80-5.04 
CHD + DM  33 (0.4) 11 (0.6) 3.57 1.70-7.50* 
CHD + IC 18 (0.2) 10 (0.6) 5.95 2.60-13.60* 
CHD + Smoking  48 (0.6) < 5 0.67 0.20-2.23 
CLD + CRD  6 (0.08) < 5 1.79 0.21-15.13 
CLD + DM 9 (0.1) < 5 1.19 0.15-9.59 
CLD + IC 10 (0.1) 7 (0.4) 7.50 2.74-20.59* 
CLD + Smoking  27 (0.3) < 5 0.79 0.18-3.44 
CRD + DM  24 (0.3) < 5 0.45 0.06-3.37 
CRD + IC 35 (0.4) 14 (0.8) 4.23 2.16-8.51* 
CRD + Smoking  224 (2.8) 13 (0.7) 0.62 0.33-1.17 
DM + IC 19 (0.2) 10 (0.6) 5.64 2.48-12.80* 
DM + Smoking  54 (0.7) 5 (0.3) 0.99 0.38-2.60 
IC + Smoking 197 (2.5) 27 (1.5) 1.47 0.89-2.42 
Three Risk factors 
1,897 
(23.8) 
480 
(27.2) 2.71 1.99-3.69* 
Age + Alcoholism + CHD 5 (0.06) < 5 2.14 0.25-18.71 
Age + Alcoholism + CLD  5 (0.06) < 5 2.14 0.25-18.71 
Age + Alcoholism + CRD  12 (0.2) 6 (0.3) 5.36 1.93-14.90* 
Age + Alcoholism + DM  < 5 0 n/a n/a 
Age + Alcoholism + IC 5 (0.06) < 5 6.43 1.49-27.7* 
Age + Alcoholism + Smoking  25 (0.3) < 5 0.86 0.19-3.73 
Age + CHD + CLD  < 5 < 5 5.36 0.96-29.99 
Age + CHD + CRD  249 (3.1) 90 (5.1) 3.87 2.65-5.66* 
Age + CHD + DM  110 (1.4) 41 (2.3) 3.99 2.51-6.35* 
Age + CHD + IC 62 (0.8) 32 (1.8) 5.53 3.30-9.28* 
Age + CHD + Smoking  28 (0.4) 9 (0.5) 3.44 1.54-7.71* 
Age + CLD + CRD  < 5 < 5 32.10 3.28-314.30* 
Age + CLD + DM   < 5 < 5 2.68 0.29-24.44 
Age + CLD + IC < 5 < 5 42.86 4.69-390.98* 
Age + CLD + Smoking  < 5 < 5 21.43 1.91-240.56* 
Age + CRD + DM  70 (0.9) 16 (0.9) 2.45 1.32-4.54* 
Age + CRD + IC 145 (1.8) 43 (2.4) 3.18 2.03-4.98* 
Age + CRD + Smoking  186 (2.4) 27 (1.5) 1.56 0.95-2.56 
Age + DM + IC 38 (0.5) 14 (0.8) 3.95 2.00-7.79* 
Age + DM + Smoking  29 (0.4) < 5 1.48 0.50-4.38 
Age + IC + Smoking  123 (1.5) 24 (1.4) 2.09 1.24-3.54* 
Alcoholism + CHD + CLD  < 5 < 5 10.71 1.48-77.69* 
Alcoholism + CHD + CRD 10 (0.1) < 5 2.14 0.46-10.06 
Alcoholism + CHD + DM  < 5 < 5 2.68 0.29-24.44 
Alcoholism + CHD + IC < 5 0 n/a n/a 
Alcoholism + CHD + Smoking  21 (0.3) < 5 1.02 0.23-4.48 
Alcoholism + CLD + CRD  12 (0.2) 5 (0.3) 4.47 1.51-13.20* 
Alcoholism + CLD + DM  < 5 < 5 8.04 1.75-36.96* 
Alcoholism + CLD + IC 9 (0.1) 5 (0.3) 5.95 1.92-18.46* 
Alcoholism + CLD + Smoking  52 (0.7) 18 (1.0) 3.71 2.01-6.83* 
Alcoholism + CRD + DM 0 0 n/a n/a 
Alcoholism + CRD + IC 7 (0.09) < 5 3.06 0.62-15.14 
Alcoholism + CRD + Smoking  128 (1.6) 5 (0.3) 0.42 0.16-1.07 
Alcoholism + DM + Smoking 0 0 n/a n/a 
Alcoholism + DM + Smoking  23 (0.3) < 5 1.40 0.41-4.82 
Alcoholism + IC + Smoking  40 (0.5) 13 (0.7) 3.48 1.75-6.95* 
CHD + CLD + CRD  < 5 < 5 2.68 0.29-24.44 
CHD + CLD + DM  < 5 < 5 10.71 2.10-54.51* 
CHD + CLD + IC < 5 < 5 5.36 0.48-60.14 
CHD + CLD + Smoking  < 5 < 5 2.68 0.29-24.44 
CHD + CRD + DM  51 (0.6) 9 (0.5) 1.89 0.88-4.07 
CHD + CRD + IC 25 (0.3) < 5 1.29 0.38-4.41 
CHD + CRD + Smoking  87 (1.1) 17 (1.0) 2.09 1.15-3.80* 
CHD + DM + IC 13 (0.2) 4 (0.2) 3.30 1.04-10.50* 
CHD + DM + Smoking  36 (0.5) < 5 0.89 0.27-3.01 
CHD + IC + Smoking  15 (0.2) 5 (0.3) 3.57 1.25-10.24* 
CLD + CRD + DM  < 5 < 5 7.14 1.17-43.78* 
CLD + CRD + IC 6 (0.08) < 5 1.79 0.21-15.13 
CLD + CRD + Smoking  17 (0.2) < 5 1.26 0.28-5.62 
CLD + DM + IC < 5 < 5 7.14 1.17-43.78* 
CLD + DM + Smoking  10 (0.1) 0 n/a n/a 
CLD + IC + Smoking 17 (0.2) < 5 2.52 0.82-7.79 
CRD + DM + IC 12 (0.2) < 5 3.57 1.11-11.49* 
CRD + DM + Smoking  50 (0.6) < 5 0.43 0.10-1.82 
CRD + IC + Smoking  101 (1.3) 23 (1.3) 2.44 1.42-4.18* 
DM + IC + Smoking  19 (0.2) 7 (0.4) 3.95 1.58-9.85* 
Four Risk factors 
1,307 
(16.5) 
399 
(22.6) 3.27 2.39-4.47* 
Age + Alcoholism + CHD + CLD  < 5 < 5 10.71 2.11-54.51* 
Age + Alcoholism + CHD + 
CRD  9 (0.1) 6 (0.3) 7.15 2.44-20.91* 
Age + Alcoholism + CHD + DM  < 5 < 5 3.57 0.37-34.99 
Age + Alcoholism + CHD + IC 0 < 5 n/a n/a 
Age + Alcoholism + CHD + 
Smoking  6 (0.08) < 5 5.36 1.30-22.09* 
Age + Alcoholism + CLD + CRD  < 5 < 5 8.04 1.75-36.96* 
Age + Alcoholism + CLD + DM  0 < 5 n/a n/a 
Age + Alcoholism + CLD + IC < 5 0 n/a n/a 
Age + Alcoholism + CLD + 
Smoking  < 5 < 5 2.68 0.29-24.44 
Age + Alcoholism + CRD + DM < 5 < 5 10.71 2.11-54.51* 
Age + Alcoholism + CRD + IC 8 (0.1) < 5 4.02 1.03-15.64* 
Age + Alcoholism + CRD + 
Smoking  39 (0.5) 7 (0.4) 1.92 0.82-4.53 
Age + Alcoholism + DM + IC < 5 0 n/a n/a 
Age + Alcoholism + DM + 
Smoking  < 5 < 5 10.71 0.66-173.96 
Age + Alcoholism + IC + 
Smoking 9 (0.1) < 5 2.38 0.50-11.33 
Age + CHD + CLD + CRD  < 5 < 5 21.43 1.91-240.56* 
Age + CHD + CLD + DM  < 5 < 5 10.71 2.60-44.17* 
Age + CHD + CLD + IC < 5 < 5 16.07 2.62-98.50* 
Age + CHD + CLD + Smoking  < 5 < 5 5.36 0.48-60.14 
Age + CHD + CRD + DM  172 (2.2) 56 (3.2) 3.49 2.29-5.31* 
Age + CHD + CRD + IC 152 (1.9) 53 (3.0) 3.74 2.43-5.73* 
Age + CHD + CRD + Smoking  162 (2.0) 47 (2.7) 3.11 2.01-4.81* 
Age + CHD + DM + IC 45 (0.6) 18 (1.0) 4.29 2.31-7.97* 
Age + CHD + DM + Smoking  24 (0.3) 5 (0.3) 2.23 0.82-6.11 
Age + CHD + IC + Smoking 24 (0.3) 8 (0.5) 3.57 1.52-8.37* 
Age + CLD + CRD + DM  < 5 0 n/a n/a 
Age + CLD + CRD + IC < 5 < 5 7.14 1.17-43.78* 
Age + CLD + CRD + Smoking  < 5 0 n/a n/a 
Age + CLD + DM + IC 6 (0.08) 0 n/a n/a 
Age + CLD + DM + Smoking  < 5 0 n/a n/a 
Age + CLD + IC + Smoking < 5 < 5 10.71 0.66-173.96 
Age + CRD + DM + IC 44 (0.6) 9 (0.5) 2.19 1.01-4.76* 
Age + CRD + DM + Smoking  43 (0.5) 6 (0.3) 1.50 0.61-3.69 
Age + CRD + IC + Smoking 120 (1.5) 36 (2.0) 3.22 2.00-5.16* 
Age + DM + IC + Smoking 15 (0.2) 6 (0.3) 4.29 1.59-11.55* 
Alcoholism + CHD + CLD + 
CRD  5 (0.06) < 5 4.29 0.81-22.68 
Alcoholism + CHD + CLD + DM  < 5 < 5 3.57 0.37-34.99 
Alcoholism + CHD + CLD + IC < 5 0 n/a n/a 
Alcoholism + CHD + CLD + 
Smoking  15 < 5 2.86 0.91-8.95 
Alcoholism + CHD + CRD + DM  < 5 0 n/a n/a 
Alcoholism + CHD + CRD + 
Smoking  57 (0.7) < 5 0.38 0.09-1.59 
Alcoholism + CHD + DM + IC 0 < 5 n/a n/a 
Alcoholism + CHD + DM + 
Smoking  9 (0.1) 0 n/a n/a 
Alcoholism + CHD + IC + 
Smoking 10 (0.1) < 5 1.07 0.134-8.55 
Alcoholism + CLD + CRD + DM  < 5 < 5 5.36 0.48-60.14 
Alcoholism + CLD + CRD + IC 5 (0.06) < 5 6.43 1.49-27.71* 
Alcoholism + CLD + CRD + 
Smoking  37 (0.5) 6 (0.3) 1.74 0.70-4.32 
Alcoholism + CLD + DM + IC < 5 < 5 32.10 3.28-314.30* 
Alcoholism + CLD + DM + 
Smoking  7 (0.1) 10 (0.6) 15.31 5.58-41.99* 
Alcoholism + CLD + IC + 
Smoking 14 (0.2) 12 (0.7) 9.18 4.03-20.95* 
Alcoholism + CRD + DM + IC < 5 0 n/a n/a 
Alcoholism + CRD + DM + 
Smoking  14 (0.2) < 5 0.77 0.10-5.94 
Alcoholism + CRD + IC + 
Smoking 40 (0.5) 13 (0.7) 3.48 1.75-6.95* 
Alcoholism + DM + IC + 
Smoking < 5 < 5 2.68 0.29-24.44 
CHD + CLD + CRD + DM  5 (0.06) < 5 2.14 0.25-18.71 
CHD + CLD + CRD + IC < 5 < 5 21.43 1.91-240.56* 
CHD + CLD + CRD + Smoking  11 (0.1) < 5 1.95 0.42-9.04 
CHD + CLD + DM + IC < 5 < 5 10.71 1.48-77.69* 
CHD + CLD + DM + Smoking  < 5 0 n/a n/a 
CHD + CLD + IC + Smoking < 5 0 n/a n/a 
CHD + CRD + DM + IC 13 (0.2) 7 (0.4) 5.77 2.20-15.13* 
CHD + CRD + DM + Smoking  53 (0.7) 17 (1.0) 3.44 1.85-6.39* 
CHD + CRD + IC + Smoking 38 (0.5) 13 (0.7) 3.67 1.83-7.34* 
CHD + DM + IC + Smoking 12 (0.2) 0 n/a n/a 
CLD + CRD + DM + IC < 5 < 5 10.71 0.66-173.96 
CLD + CRD + DM + Smoking  < 5 0 n/a n/a 
CLD + CRD + IC + Smoking 9 (0.1) < 5 2.38 0.50-11.33 
CLD + DM + IC + Smoking < 5 0 n/a n/a 
CRD + DM + IC + Smoking 9 (0.1) < 5 1.19 0.15-9.59 
Five Risk factors 584 (7.3) 
198 
(11.2) 3.63 2.60-5.07* 
Age + Alcoholism + CHD + CLD 
+ CRD  5 (0.06) < 5 4.29 0.81-22.68 
Age + Alcoholism + CHD + CLD 
+ DM 0 0 n/a n/a 
Age + Alcoholism + CHD + CLD 
+ IC 0 0 n/a n/a 
Age + Alcoholism + CHD + CLD 
+ Smoking  0 < 5 n/a n/a 
Age + Alcoholism + CHD + 
CRD + DM  5 (0.06) < 5 8.58 2.23-32.99* 
Age + Alcoholism + CHD + 
CRD + IC 7 (0.09) < 5 1.53 0.19-12.70 
Age + Alcoholism + CHD + 
CRD + Smoking  29 (0.4) 11 (0.6) 4.06 1.91-8.63* 
Age + Alcoholism + CHD + DM 
+ IC < 5 0 n/a n/a 
Age + Alcoholism + CHD + DM 
+ Smoking  < 5 0 n/a n/a 
Age + Alcoholism + CHD + IC + 
Smoking 5 (0.06) < 5 4.29 0.81-22.68 
Age + Alcoholism + CLD + CRD 
+ DM 0 0 n/a n/a 
Age + Alcoholism + CLD + CRD 
+ IC < 5 < 5 5.36 0.48-60.14 
Age + Alcoholism + CLD + CRD 
+ Smoking  11 (0.1) 0 n/a n/a 
Age + Alcoholism + CLD + DM 
+ IC < 5 0 n/a n/a 
Age + Alcoholism + CLD + DM 
+ Smoking  < 5 0 n/a n/a 
Age + Alcoholism + CLD + IC + 
Smoking < 5 < 5 5.36 0.48-60.14 
Age + Alcoholism + CRD + DM 
+ IC < 5 0 n/a n/a 
Age + Alcoholism + CRD + DM 
+ Smoking  5 (0.06) 0 n/a n/a 
Age + Alcoholism + CRD + IC + 
Smoking 14 (0.2) 8 (0.5) 6.12 2.45-15.31* 
Age + Alcoholism + DM + IC + 
Smoking < 5 0 n/a n/a 
Age + CHD + CLD + CRD + DM  < 5 < 5 3.57 0.37-34.99 
Age + CHD + CLD + CRD + IC 5 (0.06) < 5 2.14 0.25-18.71 
Age + CHD + CLD + CRD + 
Smoking  7 (0.09) 5 (0.3) 7.65 2.34-25.01* 
Age + CHD + CLD + DM + IC 0 0 n/a n/a 
Age + CHD + CLD + DM + 
Smoking 0 0 n/a n/a 
Age + CHD + CLD + IC + 
Smoking 0 < 5 n/a n/a 
Age + CHD + CRD + DM + IC 81 (1.0) 39 (2.2) 5.16 3.19-8.35* 
Age + CHD + CRD + DM + 
Smoking  79 (1.0) 19 (1.1) 2.58 1.443-4.60* 
Age + CHD + CRD + IC + 
Smoking 118 (1.5) 34 (1.9) 3.09 1.91-4.99* 
Age + CHD + DM + IC + 
Smoking 16 (0.2) < 5 2.68 0.86-8.33 
Age + CLD + CRD + DM + IC < 5 0 n/a n/a 
Age + CLD + CRD + DM + 
Smoking  < 5 0 n/a n/a 
Age + CLD + CRD + IC + 
Smoking < 5 < 5 16.07 2.62-98.50* 
Age + CLD + DM + IC + 
Smoking 0 0 n/a n/a 
Age + CRD + DM + IC + 
Smoking 26 (0.3) 11 (0.6) 4.54 2.11-9.73* 
Alcoholism + CHD + CLD + 
CRD + DM  < 5 0 n/a n/a 
Alcoholism + CHD + CLD + 
CRD + IC < 5 < 5 10.71 0.66-173.96 
Alcoholism + CHD + CLD + 
CRD + Smoking  13 (0.2) < 5 3.30 1.04-10.50* 
Alcoholism + CHD + CLD + DM 
+ IC 0 0 n/a n/a 
Alcoholism + CHD + CLD + DM 
+ Smoking  < 5 < 5 3.57 0.37-34.99 
Alcoholism + CHD + CLD + IC + 
Smoking < 5 < 5 10.71 0.66-173.96 
Alcoholism + CHD + CRD + DM 
+ IC < 5 0 n/a n/a 
Alcoholism + CHD + CRD + DM 
+ Smoking  18 (0.2) < 5 0.60 0.08-4.55 
Alcoholism + CHD + CRD + IC 
+ Smoking 16 (0.2) < 5 0.67 0.09-5.16 
Alcoholism + CHD + DM + IC + 
Smoking < 5 0 n/a n/a 
Alcoholism + CLD + CRD + DM 
+ IC < 5 < 5 10.71 0.66-173.96 
Alcoholism + CLD + CRD + DM 
+ Smoking  10 (0.1) < 5 2.14 0.46-10.06 
Alcoholism + CLD + CRD + IC + 
Smoking 16 (0.2) 10 (0.6) 6.70 2.88-15.55* 
Alcoholism + CLD + DM + IC + 
Smoking < 5 < 5 5.36 0.48-60.14 
Alcoholism + CRD + DM + IC + 
Smoking 7 (0.09) 0 n/a n/a 
CHD + CLD + CRD + DM + IC < 5 < 5 10.71 0.66-173.96 
CHD + CLD + CRD + DM + 
Smoking  8 (0.1) < 5 4.02 1.03-15.64* 
CHD + CLD + CRD + IC + 
Smoking < 5 < 5 7.14 1.17-43.78* 
CHD + CLD + DM + IC + 
Smoking 5 (0.06) < 5 4.29 0.81-22.68 
CHD + CRD + DM + IC + 
Smoking 37 (0.5) 17 (1.0) 4.92 2.58-9.38* 
CLD + CRD + DM + IC + 
Smoking 0 < 5 n/a n/a 
Six Risk factors 114 (1.4) 45 (2.6) 4.23 2.69-6.65* 
Age + Alcoholism + CHD + CLD 
+ CRD + IC < 5 < 5 10.71 0.66-173.96 
Age + Alcoholism + CHD + CLD 
+ CRD + Smoking  5 (0.06) < 5 4.29 0.81-22.68 
Age + Alcoholism + CHD + CLD 
+ CRD + DM  < 5 < 5 10.71 0.66-173.96 
Age + Alcoholism + CHD + CLD 
+ DM + IC 0 0 n/a n/a 
Age + Alcoholism + CHD + CLD 
+ DM + Smoking  < 5 0 n/a n/a 
Age + Alcoholism + CHD + CLD 
+ IC + Smoking 0 < 5 n/a n/a 
Age + Alcoholism + CHD + 
CRD + DM + IC 0 0 n/a n/a 
Age + Alcoholism + CHD + 
CRD + DM + Smoking  11 (0.1) < 5 2.92 0.79-10.83 
Age + Alcoholism + CHD + 
CRD + IC + Smoking 13 (0.2) 7 (0.4) 5.77 2.20-15.13* 
Age + Alcoholism + CHD + DM 
+ IC + Smoking 0 0 n/a n/a 
Age + Alcoholism + CLD + CRD 
+ DM + IC 0 < 5 n/a n/a 
Age + Alcoholism + CLD + CRD 
+ DM + Smoking  < 5 < 5 10.71 0.66-173.96 
Age + Alcoholism + CLD + CRD 
+ IC + Smoking < 5 < 5 21.43 1.91-240.56* 
Age + Alcoholism + CLD + DM 
+ IC + Smoking 0 0 n/a n/a 
Age + Alcoholism + CRD + DM 
+ IC + Smoking < 5 0 n/a n/a 
Age + CHD + CLD + CRD + DM 
+ IC < 5 < 5 5.36 0.96-29.99 
Age + CHD + CLD + CRD + DM 
+ Smoking  < 5 0 n/a n/a 
Age + CHD + CLD + CRD + IC 
+ Smoking < 5 < 5 10.71 2.11-54.51* 
Age + CHD + CLD + DM + IC + 
Smoking 0 0 n/a n/a 
Age + CHD + CRD + DM + IC + 
Smoking 34 (0.4) 10 (0.6) 3.15 1.47-6.76* 
Age + CLD + CRD + DM + IC + 
Smoking < 5 < 5 5.36 0.48-60.14 
Alcoholism + CHD + CLD + 
CRD + DM + IC < 5 0 n/a n/a 
Alcoholism + CHD + CLD + 
CRD + DM + Smoking  7 (0.09) < 5 4.59 1.15-18.32* 
Alcoholism + CHD + CLD + 
CRD + IC + Smoking 6 (0.08) < 5 7.14 1.95-26.17* 
Alcoholism + CHD + CLD + DM 
+ IC + Smoking < 5 0 n/a n/a 
Alcoholism + CHD + CRD + DM 
+ IC + Smoking 5 (0.06) < 5 2.14 0.25-18.71 
Alcoholism + CLD + CRD + DM 
+ IC + Smoking < 5 < 5 5.36 0.96-29.99 
CHD + CLD + CRD + DM + IC 
+ Smoking < 5 0 n/a n/a 
Seven Risk factors 13 (0.2) < 5 2.47 0.68-8.98 
Age + Alcoholism + CHD + CLD 
+ CRD + DM + IC < 5 0 n/a n/a 
Age + Alcoholism + CHD + CLD 
+ CRD + DM + Smoking  0 < 5 n/a n/a 
Age + Alcoholism + CHD + CLD 
+ CRD + IC + Smoking < 5 0 n/a n/a 
Age + Alcoholism + CHD + CLD 
+ DM + IC + Smoking 0 < 5 n/a n/a 
Age + Alcoholism + CHD + 
CRD + DM + IC + Smoking < 5 0 n/a n/a 
Age + Alcoholism + CLD + CRD 
+ DM + IC + Smoking < 5 < 5 10.71 0.66-173.96 
Age + CHD + CLD + CRD + DM 
+ IC + Smoking < 5 0 n/a n/a 
Alcoholism + CHD + CLD + 
CRD + DM + IC + Smoking < 5 0 n/a n/a 
Eight Risk factors 5 (0.06) < 5 2.14 0.25-18.71 
Age + Alcoholism + CHD + CLD 
+ CRD + DM + IC + Smoking 5 (0.06) < 5 2.14 0.25-18.71 
 
 
Age, Age ≥ 65 years; CHD, Chronic Heart Disease; CLD, Chronic Liver Disease; 
CRD, Chronic Respiratory Disease; CI, Confidence Interval; DM, Diabetes 
Mellitus; IC, Immunodeficiency; OR, Odds Ratio 
*p < 0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
